Eculizumab is a first-in-class complement inhibitor and a humanized monoclonal antibody that binds to C5, thereby inhibiting the formation of the terminal components of the complement cascade. Recently, the use of eculizumab in pediatric patients with HCT-TMA has been reported. 11 Here we describe five adult patients who developed symptoms and signs of HCT-TMA and were treated with eculizumab. Four out of five patients demonstrated improvement in hematologic and renal parameters, but two patients succumbed to infectious complications from treatment of exacerbation of pre-existing GvHD. Plasma biomarkers of complement activation were studied to assist in the clinical evaluation and the treatment of TMA.
Patient demographics, mode of presentation and HCT complications were abstracted from the medical record. Patients were consented to an institutional review board-approved protocol for studying complement activation in patients with TMA findings. TMA was diagnosed using current diagnostic criteria, which include elevated lactate dehydrogenase (LDH) above normal, haptoglobin below the lower limit of normal, schistocytosis, anemia, thrombocytopenia, negative Coombs' test and acute kidney injury defined as a doubling of the serum creatinine compared with the patient's pre-HCT baseline. 5, 6 Proteinuria was detected using a random spot urine protein-to-creatinine ratio (normal o 0.2 mg/mg). Organ biopsy was performed when clinically indicated and reviewed for histology and EM.
Complement biomarkers were studied in plasma samples obtained at the time of the diagnosis of HCT-TMA and included biomarkers of the alternative pathway (Bb), classical/lectin pathway (C4d) and terminal pathway (C5b-9 and C5a). 12 Complement biomarker studies and the ADAMTS13 activity studies were performed in a CLIA-approved lab at the Ohio State University.
Eculizumab therapy was initiated at the Food and Drug Administration-approved dosing schedule for aHUS: 900 mg intravenously weekly for the first 4 weeks, then 1200 mg intravenously every other week beginning on week 5 for a total of 8 weeks. Patients who did not have improvement in renal function were treated for longer course. Patients received meningococcal vaccines and were maintained on ciprofloxacin for 2 weeks as primary prophylaxis against Neisseria meningitidis. Table 1 shows baseline characteristics of these patients and response characteristics after eculizumab treatment. All five patients had evidence of anemia, thrombocytopenia, elevated serum creatinine and LDH, with normal ADAMTS13 levels. All patients were on tacrolimus at the time of TMA diagnosis and subsequently, tacrolimus was discontinued in all five patients. On histologic and EM evaluation, three out of four patients who had renal biopsies showed features suggestive of TMA. Despite discontinuation of tacrolimus, hematologic and renal parameters continued to worsen. When there was a clinical suspicion of HCT-TMA, complement levels were used to help support use of eculizumab. Patient 1 had concomitant cardiac manifestations that included a pericardial effusion and decreased systolic heart function. Patients 2, 3 and 4 had renal manifestations; patient 5 had hypoxia of unclear etiology and comprehensive evaluation did not show pulmonary embolism or bronchiolitis obliterans syndrome. Renal biopsy of patients showed obliteration of glomerulo-capillary loops and glomeruli containing fragmented RBC. Lung biopsy of patient 5 showed eccentric intimal thickening of pulmonary arterioles with fresh organizing thrombus.
The following criteria were used for initiation of eculizumab: (i) transfusion-dependent anemia/thrombocytopenia; (ii) elevated LDH; (iii) end-organ damage (renal, lung and hypertension); (iv) lack of improvement for at least 4 weeks after cessation of tacrolimus; and (iv) absence of an alternative etiology. As shown in Figure 1 , improvement in platelet counts preceded improvement in creatinine after starting eculizumab. Patient 1 had resolution of pericardial effusion with recovery to normal systolic function within 12 weeks; patient 5 had resolution of hypoxia. Responses of patients 1, 2, 3 and 5 are shown in Figure 1 .
The clinical course of patients 3 and 4 are instructive as to treatment of HCT-TMA with concomitant GvHD. Both patients were on high-dose steroids at the time of initiation of eculizumab. While patient 3 had hematologic improvement and improvement in renal function, she was already on renal replacement therapy at time of diagnosis. She developed catheter-associated methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and succumbed to sepsis. Patient 4 had been started on high-dose steroids a week before eculizumab for biopsy-proven late onset de novo acute skin GvHD. After three doses of eculizumab, he presented with hypotension, worsening liver GvHD and was noted to have pseudomonal sepsis. Despite maximal supportive care, he succumbed to pseudomonal sepsis.
The etiology of HCT-TMA has been postulated to be from endothelial damage due to conditioning regimen, calcineurin Abbreviations: AKI = acute kidney injury; CHF = congestive heart failure; HCT-TMA = hematopoietic cell transplant-thrombotic microangiopathy; HTN = hypertension; MRSA = methicillin-resistant Staphylococcus aureus; NA = not applicable.
inhibitors or sirolimus. 7, 8, 13, 14 In the first prospective study of TMA in pediatric patients, incidence was reported to be as high as 35% and presence of TMA associated with higher non-relapse mortality than in patients without TMA. 1 Jodele et al. 15 proposed that TMA is characterized by multi-organ endothelial injury affecting kidneys, gut, serosal surfaces, heart, skin and lungs, all in the setting of hemolytic anemia and thrombocytopenia. Martinez et al. 16 studied 221 consecutive patients and noted a 31% incidence of TMA at 100 days post HCT. In our series, TMA appeared to be a later event than reported in the literature; one of the reasons could be continued use of tacrolimus in the setting of concomitant GvHD.
We show that in HCT-TMA, eculizumab was able to halt worsening of end-organ damage and achieve transfusion independence. We also observed that cardiac and pulmonary manifestations can occur with HCT-TMA and can be reversed with eculizumab. Platelet recovery preceded renal improvement; resolution of severe renal injury took several weeks in the first patient, which is consistent with the published literature demonstrating the time-dependent recovery of renal injury in patients with aHUS. 10 Our study provides important information about the role of complement activation and efficacy of eculizumab in adults with HCT-TMA and validates the experience in pediatric patients. 11 All pediatric responders showed continuous, time-dependent improvement in renal function and hematologic parameters with eculizumab. Jodele et al. showed that with early detection and use of eculizumab, shorter courses of therapy are adequate to forestall progression of renal and pulmonary end-organ damage. It is important to mention that the measurement of plasma biomarkers of C5a and C5b-9 are surrogates for the formation of the membrane attack complex that is a cellular event. Therefore, the markers of terminal activation may not be sufficiently sensitive in all patients with terminal complement activation as reported by Noris et al. 17 For this reason, complement biomarkers should be viewed as one additional piece of data to diagnose patients with a complement-mediated TMA, and not be used alone to exclude the diagnosis of a HCT-TMA.
Treatment with eculizumab carries a heightened risk of infections caused by Neisseria species, and patients must receive meningococcal vaccine before starting eculizumab and it must be repeated at 2 months. Patients should be counseled appropriately about the signs and symptoms of meningococcal infection with a low threshold for treatment. 18 Concomitant chronic GvHD with prolonged use of high-dose steroids does increase likelihood of opportunistic infections; whether eculizumab therapy increases vulnerability to infections in HCT-TMA remains to be determined.
Traditionally, endothelial damage has been postulated to be the cause of HCT-TMA. Recent evidence about the role of complement activation in aHUS raises the possibility for a similar pathogenesis in HCT-TMA. We postulate that complement activation is one of the causes for HCT-TMA resulting in manifestations similar to that seen in aHUS (renal abnormalities, thrombocytopenia and microangiopathic hemolytic anemia). Until we have evidence from larger groups of patients, the clinician has to contend with a collective analysis of easily available laboratory parameters and utilize complement biomarker levels as a biomarker to help decide Letter to the Editor whether complement inhibition is reasonable. Further studies evaluating the role of complement in a prospective setting post HCT are necessary to better understand the pathophysiology of this devastating medical complication of transplant.
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